NYSE:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis $1.17 -0.08 (-6.40%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$1.17 0.00 (0.00%) As of 07:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Actinium Pharmaceuticals Stock (NYSE:ATNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ATNM alerts:Sign Up Key Stats Today's Range$1.15▼$1.2750-Day Range$0.98▼$1.5252-Week Range$0.95▼$1.95Volume105,681 shsAverage Volume156,573 shsMarket Capitalization$36.71 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingBuy Company Overview Actinium Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants. In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML. The company also has exploratory programs leveraging its antibody‐targeted alpha‐conjugate (ATAC) platform in other hematologic and solid tumor indications. These programs are designed to advance precision oncology by combining the targeting specificity of antibodies with the high‐energy, short‐range properties of alpha‐emitting isotopes. Actinium collaborates with leading academic research institutions to advance its clinical programs, and its development strategy is supported by orphan drug designations and fast‐track status from regulatory authorities. The company is incorporated in Delaware, headquartered in New York City, and conducts clinical trials primarily in the United States. Its management team brings expertise in oncology drug development, radiochemistry, and regulatory affairs to drive its late‐stage assets toward potential commercialization.AI Generated. May Contain Errors. Read More Actinium Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreATNM MarketRank™: Actinium Pharmaceuticals scored higher than 65% of companies evaluated by MarketBeat, and ranked 315th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.Upside PotentialActinium Pharmaceuticals has a consensus price target of $4.50, representing about 284.6% upside from its current price of $1.17.Amount of Analyst CoverageActinium Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Actinium Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATNM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.83 News SentimentActinium Pharmaceuticals has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Actinium Pharmaceuticals this week, compared to 1 article on an average week.Search Interest8 people have searched for ATNM on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.60% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by Institutions27.50% of the stock of Actinium Pharmaceuticals is held by institutions.Read more about Actinium Pharmaceuticals' insider trading history. Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATNM Stock News HeadlinesActinium Pharmaceuticals Inc ATNMMay 16 at 7:57 PM | morningstar.comMActinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate OptimizationMay 6, 2026 | prnewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.May 19 at 1:00 AM | Banyan Hill Publishing (Ad)Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer ...April 23, 2026 | finance.yahoo.comActinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 ...April 23, 2026 | finance.yahoo.comActinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual MeetingApril 22, 2026 | prnewswire.comActinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual MeetingApril 22, 2026 | prnewswire.comSLS vs ATNM: Which cancer stock has bigger upside ahead of fresh data reveal?April 20, 2026 | msn.comSee More Headlines ATNM Stock Analysis - Frequently Asked Questions How have ATNM shares performed this year? Actinium Pharmaceuticals' stock was trading at $1.36 at the start of the year. Since then, ATNM stock has decreased by 14.0% and is now trading at $1.17. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSE:ATNM) posted its earnings results on Monday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02. When did Actinium Pharmaceuticals' stock split? Actinium Pharmaceuticals's stock reverse split on the morning of Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Actinium Pharmaceuticals' major shareholders? Top institutional investors of Actinium Pharmaceuticals include Renaissance Technologies LLC (1.50%). View institutional ownership trends. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK), Company Calendar Last Earnings8/05/2024Today5/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ATNM's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ATNM Previous SymbolNYSE:ATNM CIK1388320 WebN/A Phone(646) 677-3870FaxN/AEmployees30Year Founded2000Price Target and Rating Average Price Target for Actinium Pharmaceuticals$4.50 High Price Target$5.00 Low Price Target$4.00 Potential Upside/Downside+284.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.82 million Net MarginsN/A Pretax Margin-50,512.35% Return on Equity-100.85% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.25 Sales & Book Value Annual Sales$90 thousand Price / Sales407.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.89Miscellaneous Outstanding Shares31,375,000Free Float29,324,000Market Cap$36.71 million OptionableOptionable Beta-0.11 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:ATNM) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
